A comprehensive view of merck & co. inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Health Canada approves Merck & Co's KEYTRUDA in combination with chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma treatment following successful Phase 3 trial
Published: April 19, 2024 by EquityBites
Research by Merck & Co. suggests that in-silico models can help determine design space for cell culture processes, assisting in understanding their operating parameters and limits; study data may improve bioreactor usage
Published: April 19, 2024 by Chemicals & Chemistry Business Daily
Merck to acquire the University at Buffalo startup Abceutics for up to US$280.0M in a bid to enhance its antibody-drug conjugate pipeline; Abceutics is developing technology aimed at reducing the impact of therapies on healthy cells
Published: April 08, 2024 by FierceBiotech
Merck initiates Phase 3 clinical trial of MK-1084, an investigational oral KRAS G12C inhibitor, in combination with KEYTRUDA (pembrolizumab) for first-line treatment of certain patients with metastatic non-small cell lung cancer
Published: April 04, 2024 by Merck & Co. Inc.
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients With Platinum-Resistant Ovarian Cancer
Published: April 03, 2024 by Merck & Co. Inc.

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count